133174-15-9

Basic information

• Product Name: Fmoc-L-citrulline
• Synonyms: Nα-[(9H-Fluoren-9-ylMethoxy)carbonyl]-L-citrulline;(S)-2-((((9H-fluoren-9-yl)Methoxy)carbonyl)aMino)-5-ureidopentanoic acid;Fmoc-Cit-OH >=97.0% (HPLC);(S)-2-Fmoc-amino-5-ureidopentanoic acid;Fmoc-L-citrulline≥ 98% (HPLC);Fmoc-L-Orn(carbamoyl)-OH;FMOC-ORN(CARBAMOYL)-OH;FMOC-L-2-AMINO-5-UREIDO-N-VALERIC ACID
• CAS NO: 133174-15-9
• Molecular Formula: C21H23N3O5
• Molecular Weight: 397.42
• Product Categories: Amino Acids;Citruline [Cit];Unusual Amino Acids;Fmoc-Amino acid series
• Mol File: 133174-15-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 671.5oC at 760 mmHg
• Flash Point: 359.9oC
• Appearance: /Solid
• Density: 1.316g/cm3
• Vapor Pressure: 6.01E-19mmHg at 25°C
• Refractive Index: -10 ° (C=1, DMF)
• Storage Temp.: 2-8°C
• PKA: 3.84±0.21(Predicted)
• BRN: 7780987
• CAS DataBase Reference: Fmoc-L-citrulline(CAS DataBase Reference)
• NIST Chemistry Reference: Fmoc-L-citrulline(133174-15-9)
• EPA Substance Registry System: Fmoc-L-citrulline(133174-15-9)

Safety Data

• WGK Germany: 3
• F: 10
• HazardClass: IRRITANT
• Hazardous Substances Data: 133174-15-9(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C21H23N3O5/c22-20(27)23-11-5-10-18(19(25)26)24-21(28)29-12-17-15-8-3-1-6-13(15)14-7-2-4-9-16(14)17/h1-4,6-9,17-18H,5,10-12H2,(H,24,28)(H,25,26)(H3,22,23,27)/t18-/m0/s1

Upstream product

• 372-75-8 Citrulline 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 

Downstream Products

• 1639351-92-0 N-((S)-1-(((S)-1-((4-(chloromethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide 

Relevant articles and documents

A Wireframe DNA Cube: Antibody Conjugate for Targeted Delivery of Multiple Copies of Monomethyl Auristatin E

In recent years, several antibody drug conjugates (ADC) have been accepted by the FDA as therapeutics against cancer. It is well-known that control of drug-to-antibody ratio (DAR) is vital for the success of an ADC, which inspires the advancement of bette

DRUG-LINKER CONJUGATE PHARMACEUTICAL COMPOSITIONS

Compositions are disclosed having a cytotoxic and/or vascular disrupting agent (VDA) payload attached to a linker. The linker can be a cathepsin B protease cleavable linker or a non-cleavable linker that may degrade intracellularly. Methods for making and using the compositions are also provided. The compositions can be provided to a patient in need thereof with the composition coming into contact with a cancer cell to activate or release the cytotoxic and/or vascular disrupting agent payload.

QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to antibody-drug conjugates represented by Formula (I) Ab- (L-D)p, Ab is an antibody; p is 1-8; L-D is a chemical moiety represented by the following formula -Str-(Pep)-Sp-D; Str is a stretcher unit covalently attached to Ab; Pep is a linker; D is anti-tumor agent represented by the following formula wherein Rand Rare each independently Ct-C6alkyl, and Ris a non-hydrogen substituent; or Ris C1-C6alkyl, and Rand Rtogether with the N form a substituted C3-C7heterocycloalkyl ring; or R° is absent, and Rand Rtogether with the N form a substituted heteroaryl ring; Sp-D is a spacer moiety of fomula: This invention also relates to a method of treating cancer, use of antibody-drug conjugates of Formula (I) in therapy, and use of antibody-drug conjugates of Formula (I) in manufacturing a medicament for treating cancer. This invention also relates to method of preparing antibody-drug conjugates of Formula (I).